Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M van Loenen

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Haematologica|December 17, 2013
A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cellsMarleen M van Loenen, Renate de Boer, Ellis van Liempt, et al.
Pharmaceutical Research|December 14, 2004
Pharmacokinetic and biodistribution profile of recombinant human interleukin-10 following intravenous administration in rats with extensive liver fibrosisHeni Rachmawati, Leonie Beljaars, Catharina Reker-Smit, et al.
Cancer Research|February 19, 2009
Kinetic preservation of dual specificity of coprogrammed minor histocompatibility antigen-reactive virus-specific T cellsMarleen M van Loenen, Renate S Hagedoorn, Michel G D Kester, et al.
Gene Therapy|February 1, 2013
Multi-cistronic vector encoding optimized safety switch for adoptive therapy with T-cell receptor-modified T cellsM M van Loenen, R de Boer, R S Hagedoorn, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 10, 2011
Rapid re-expression of retrovirally introduced versus endogenous TCRs in engineered T cells after antigen-specific stimulationMarleen M van Loenen, Renate S Hagedoorn, Renate de Boer, et al.
Haematologica|November 27, 2010
Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignanciesMarleen M van Loenen, Renate de Boer, Renate S Hagedoorn, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 28, 2005
Renal-selective delivery and angiotensin-converting enzyme inhibition by subcutaneously administered captopril-lysozymeJai Prakash, Annemiek M van Loenen-Weemaes, Marijke Haas, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 4, 2007
Functional human antigen-specific T cells produced in vitro using retroviral T cell receptor transfer into hematopoietic progenitorsAnja U van Lent, Maho Nagasawa, Marleen M van Loenen, et al.
Journal for Immunotherapy of Cancer|March 15, 2022
T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasionLaura T Morton, Tassilo L A Wachsmann, Miranda H Meeuwsen, et al.
Pharmaceutical Research|January 10, 2008
Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosisJai Prakash, Martin H de Borst, Annemiek M van Loenen-Weemaes, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Haematologica|December 17, 2013
A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cellsMarleen M van Loenen, Renate de Boer, Ellis van Liempt, et al.
Pharmaceutical Research|December 14, 2004
Pharmacokinetic and biodistribution profile of recombinant human interleukin-10 following intravenous administration in rats with extensive liver fibrosisHeni Rachmawati, Leonie Beljaars, Catharina Reker-Smit, et al.
Cancer Research|February 19, 2009
Kinetic preservation of dual specificity of coprogrammed minor histocompatibility antigen-reactive virus-specific T cellsMarleen M van Loenen, Renate S Hagedoorn, Michel G D Kester, et al.
Gene Therapy|February 1, 2013
Multi-cistronic vector encoding optimized safety switch for adoptive therapy with T-cell receptor-modified T cellsM M van Loenen, R de Boer, R S Hagedoorn, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 10, 2011
Rapid re-expression of retrovirally introduced versus endogenous TCRs in engineered T cells after antigen-specific stimulationMarleen M van Loenen, Renate S Hagedoorn, Renate de Boer, et al.
Haematologica|November 27, 2010
Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignanciesMarleen M van Loenen, Renate de Boer, Renate S Hagedoorn, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 28, 2005
Renal-selective delivery and angiotensin-converting enzyme inhibition by subcutaneously administered captopril-lysozymeJai Prakash, Annemiek M van Loenen-Weemaes, Marijke Haas, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 4, 2007
Functional human antigen-specific T cells produced in vitro using retroviral T cell receptor transfer into hematopoietic progenitorsAnja U van Lent, Maho Nagasawa, Marleen M van Loenen, et al.
Journal for Immunotherapy of Cancer|March 15, 2022
T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasionLaura T Morton, Tassilo L A Wachsmann, Miranda H Meeuwsen, et al.
Pharmaceutical Research|January 10, 2008
Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosisJai Prakash, Martin H de Borst, Annemiek M van Loenen-Weemaes, et al.
Pageof 4